Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC Genito-Urinary Group Report
- 1 November 1986
- journal article
- Published by Springer Nature in World Journal of Urology
- Vol. 4 (3) , 176-181
- https://doi.org/10.1007/bf00327016
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II studyWorld Journal of Urology, 1986
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985
- A reexamination of the stable category for evaluating response in patients with advanced prostate cancerCancer, 1984
- Treatment of metastatic prostate cancer an analysis of response criteria in patients with measurable soft tissue diseaseCancer, 1984
- An EORTC phase II study of vindesine in advanced prostate cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Prostatic CarcinomaSouthern Medical Journal, 1980
- Treatment of Metastatic Endocrine-Unresponsive Carcinoma of the Prostate Gland With Multiagent Chemotherapy: indicators of Response to Therapy2JNCI Journal of the National Cancer Institute, 1979